In 2010, Cellectis acquired the assets, including the intellectual property, of Cyto Pulse Sciences Inc., a US-based company specialized in the development, manufacturing and commercialization of electroporation technology and equipment.
Cellectis therapeutics now continues the development of electroporation systems for use in the therapeutic field, in particular:
- DermaVax™, an in vivo intradermal electroporation system with applications in DNA vaccine delivery and gene therapy
- Large Volume Transfection Systems (LVT), for high yield ex vivo and in vitro transfection of large cell volumes, with applications in cell therapy, including immunotherapy
All Cellectis therapeutics’ electroporation systems use our patented Pulse Agile® waveforms.
Cellectis therapeutics has rights under patents, patent applications, and other intellectual property on these devices. They are supplied under license agreement from Cellectis therapeutics for all steps related to clinical applications.For further information please contact us at firstname.lastname@example.org.